IN2015DN01371A - - Google Patents

Download PDF

Info

Publication number
IN2015DN01371A
IN2015DN01371A IN1371DEN2015A IN2015DN01371A IN 2015DN01371 A IN2015DN01371 A IN 2015DN01371A IN 1371DEN2015 A IN1371DEN2015 A IN 1371DEN2015A IN 2015DN01371 A IN2015DN01371 A IN 2015DN01371A
Authority
IN
India
Prior art keywords
ifn
fusion protein
present
protein
interferon
Prior art date
Application number
Inventor
Yong Soo Bae
Seung Ho Hong
Young Hoon Kim
Seung Soo Han
Jin Kim
Original Assignee
Jw Creagene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jw Creagene Inc filed Critical Jw Creagene Inc
Publication of IN2015DN01371A publication Critical patent/IN2015DN01371A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention relates to IFN a fusion protein in which a cytoplasmic transduction peptide (CTP) and polyethylene glycol (PEG) are bonded to an IFN a protein. The IFN a fusion protein of the present invention is characterized in that the specific activity of interferon remains high the half life of the INF a fusion protein is extended when delivered in vivo and the mobility of the interferon in a liver is improved. The IFN a fusion protein of the present invention can be used in the development of protein drugs effective in preventing or treating liver diseases including various types of viral infections or the like.
IN1371DEN2015 2012-08-13 2013-08-07 IN2015DN01371A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20120088610 2012-08-13
PCT/KR2013/007136 WO2014027789A1 (en) 2012-08-13 2013-08-07 Interferon-alpha fusion protein in which cytoplasmic transduction peptide and polyethylene glycol are bonded to one another

Publications (1)

Publication Number Publication Date
IN2015DN01371A true IN2015DN01371A (en) 2015-07-03

Family

ID=50685640

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1371DEN2015 IN2015DN01371A (en) 2012-08-13 2013-08-07

Country Status (6)

Country Link
US (1) US9682152B2 (en)
JP (1) JP6010227B2 (en)
KR (1) KR102012025B1 (en)
CN (1) CN104583240B (en)
IN (1) IN2015DN01371A (en)
WO (1) WO2014027789A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104987381B (en) * 2015-06-11 2018-11-27 吉林大学 Recombinate positive charge polypeptide interferon and the application in antitumor and antiviral therapy
US20220378925A1 (en) * 2019-09-26 2022-12-01 Orionis Biosciences, Inc. Conjugated chimeric proteins
KR20230099956A (en) * 2021-12-28 2023-07-05 제이더블유크레아젠 주식회사 Polypeptide for Delivering Antigen to Immune Cells

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60329089D1 (en) 2002-03-29 2009-10-15 Creagene Inc CYTOPLASMATIC TRANSDUCTION PEPTIDES AND ITS USES
EP1917037A2 (en) 2005-08-15 2008-05-07 F.Hoffmann-La Roche Ag Peg-ifn alpha and ribavirin for hbv treatment
JP2010529859A (en) * 2007-06-15 2010-09-02 ジェンザイム、コーポレーション Fusion protein containing two TGF-β binding domains of TGF-β type II receptor
US20090286725A1 (en) * 2008-05-15 2009-11-19 Fibrex Medical Research & Development Gmbh Peptides and derivatives thereof, the manufacturing thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition
KR101183826B1 (en) * 2009-03-27 2012-09-18 제이더블유중외제약 주식회사 IFN-a Fusion Protein Comprising Interferon-a and Cytoplasmic Transduction Peptide
WO2010110503A1 (en) * 2009-03-27 2010-09-30 주식회사 중외제약 INTERFERON-α (IFN-α) FUSED PROTEIN HAVING IFN-α AND CYTOPLASMIC TRANSDUCTION PEPTIDE (CTP)
CN101942026B (en) * 2010-10-14 2014-08-27 成都正能生物技术有限责任公司 Long-acting interferon fusion protein and application thereof

Also Published As

Publication number Publication date
CN104583240A (en) 2015-04-29
US20150202312A1 (en) 2015-07-23
JP6010227B2 (en) 2016-10-19
KR20150063375A (en) 2015-06-09
CN104583240B (en) 2017-11-28
JP2015526084A (en) 2015-09-10
KR102012025B1 (en) 2019-08-19
WO2014027789A1 (en) 2014-02-20
US9682152B2 (en) 2017-06-20

Similar Documents

Publication Publication Date Title
NZ749962A (en) Pegylated porcine interferon and methods of use thereof
MX2019011215A (en) Nucleic acids encoding crispr-associated proteins and uses thereof.
PH12019501414A1 (en) Amino acid compositions and methods for the treatment of liver diseases
PH12020550258A1 (en) Trispecific proteins and methods of use
WO2017058892A3 (en) Methods and compositions for antibody-evading virus vectors
TW201613958A (en) MIC-1 fusion proteins and uses thereof
MX2018013981A (en) Improved peptide pharmaceuticals for insulin resistance.
MY196882A (en) Recombinant binding proteins and their use
IL212184A (en) Vector for conditionally expressing protein(s) having the function of immunomodulator(s), immune engineered cells, a pharmaceutical composition comprising same and use thereof for preparation of a medicament
WO2014145159A3 (en) Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use
EA200602137A1 (en) HYDROGEL PREPARATIONS OF INTERFERON
GB2496337A (en) Combination pharmaceutical composition and methods of treating diseases or conditions associated with neurodegenerative diseases
MX2021008207A (en) Multi-functional fusion proteins and uses thereof.
WO2015031726A3 (en) Engineered primate l-methioninase for therapeutic purposes
MX2014004814A (en) Compounds and methods for enhancing innate immune responses.
PH12017500450A1 (en) Flavivirus virus like particle
IN2014DN06920A (en)
IN2014DN03213A (en)
MX2019006943A (en) Polypeptides for managing viral infections.
MY168778A (en) Oligonucleotide chelate complex-polypeptide compositions and methods
IN2015DN01371A (en)
EP3362048A4 (en) Composition for intraoral delivery of biologically active peptides and proteins
IN2014CN00510A (en)
BR112014028951A2 (en) ledgf peptides and their formulations for treating degenerative disorders
IL287987A (en) Improved lyophilized formulations involving hyaluronic acid and plasmatic proteins, and uses thereof